ClinicalTrials.gg
RecruitingNCT07601243Updated Nov 12, 2026

Study of GS-2426 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GS-2426 in Advanced Solid Tumors, sponsored by Gilead Sciences. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 12, 2026First site in Spain4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.

The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants 18 years of age or older (≥ 19 years old for participants in South Korea).
  • or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatment options.
  • Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient.
  • Adequate organ function
  • (ECOG) performance status of 0 or 1
  • All participants must provide a pretreatment tumor tissue sample.

Key Exclusion Criteria:

  • Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention.
  • Have not recovered (ie, returned to Grade 1 or baseline) from adverse events (AEs) due to a previously administered agent or a previous intervention as assessed by the investigator.
  • Active second . Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled.
  • Requirement for ongoing therapy with any prohibited medications .
  • Prior therapy with a protein arginine methyltransferase 5 (PRMT5) inhibitor or methionine adenosine transferase 2a (MAT2A) inhibitor.
  • Have serious infection requiring antibiotics within 14 days prior to the first dose.
  • Uncontrolled concurrent diseases

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Phase 1a: Monotherapy Dose Escalation

    Participants will receive escalating doses of GS-2426 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 week, whichever occurs first.

    Drug: GS-2426

  • Experimental
    Phase 1b: Monotherapy Dose Expansion

    Participants will be enrolled in different indication-specific cohorts. Participants will receive GS-2426 monotherapy at the recommended dose until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 weeks, whichever occurs first.

    Drug: GS-2426

Interventions

  • DrugGS-2426

    Administered Orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE)

    Time frame: First dose up to 30 days post last dose (up to 105 weeks)

  2. Percentage of Participants Experiencing Clinical Laboratory Abnormalities

    Time frame: First dose up to 30 days post last dose (up to 105 weeks)

  3. Percentage of Participants Experiencing Any Dose-limiting Toxicities (DLTs)

    Time frame: First dose up to 21 days post first dose

  4. Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD)

    Time frame: First dose up to 21 days post first dose

  5. Recommended Phase 2 Dose (RP2D)

    Time frame: Predose to end of study (up to 105 weeks)

Secondary outcomes

  1. Plasma Concentration of GS-2426

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  2. Pharmacokinetic (PK) Parameter: AUC0-24h of GS-2426

    AUC0-24h is defined as the area under concentration versus time from 0 to 24 hours.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  3. PK Parameters: Cmax of GS-2426

    Cmax is defined as the maximum observed plasma drug concentration.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

  4. PK Parameters: Tmax of GS-2426

    Tmax is defined as the time to peak plasma drug concentration of GS-2426.

    Time frame: Predose and postdose up to end of treatment (up to 105 weeks)

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first site in Spain
Show 4 added (3 Spain, 1 United States)
  • Beth Israel Deaconess Medical Center · Boston, United States
  • START Madrid- CIOCC - Hospital HM Sanchinarro · Madrid, Spain
  • Vall d'Hebron Institute of Oncology (VHIO) · Barcelona, Spain
  • START Madrid-FJD - Hospital Fundación Jiménez Díaz · Madrid, Spain
across 2 updates, Oct 14, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    2 sites added
    Show 2 added (2 Spain)
    • Vall d'Hebron Institute of Oncology (VHIO) · Barcelona, Spain
    • START Madrid-FJD - Hospital Fundación Jiménez Díaz · Madrid, Spain
    + 1 other change: verification date
  2. Oct 14, 2026
    2 sites added — first site in Spain
    Show 2 added (1 United States, 1 Spain)
    • Beth Israel Deaconess Medical Center · Boston, United States
    • START Madrid- CIOCC - Hospital HM Sanchinarro · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07601243
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 2, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion